|
|
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismRHO gene transference |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingNot ApplicableIIT Clinical Study on Preliminary Safety and Efficacy of Gene Replacement Drug ZVS106e Injection for Hereditary Retinal Degenerations (IRDs) Caused by Biallelic Mutations in the ABCA4 Gene
/ Not yet recruitingPhase 1/2 A Single-Arm, Open-Label, Phase 1/2 Clinical Trial of ZVS203e in Subjects With Retinitis Pigmentosa Associated With RHO Mutation
This trial employs a single-arm, open-label seamless Phase I/II design, consisting of two stages: Phase I dose exploration and Phase II dose expansion.The primary objective of this trial is to evaluate the safety, tolerability, and efficacy of subretinal injection of ZVS203e solution.
A Multicenter, Randomized,Controlled,Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of ZVS101e Administered as a Single Subretinal Injection in Subjects With Bietti's Crystalline Dystrophy (BCD)
This is a multi-center, randomized and controlled phase 3 clinical trial.
100 Clinical Results associated with Beijing Chigenovo Co., Ltd.
0 Patents (Medical) associated with Beijing Chigenovo Co., Ltd.
100 Deals associated with Beijing Chigenovo Co., Ltd.
100 Translational Medicine associated with Beijing Chigenovo Co., Ltd.